BioLife Solutions (BLFS)
(Delayed Data from NSDQ)
$17.53 USD
+0.67 (3.97%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $17.53 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BLFS 17.53 +0.67(3.97%)
Will BLFS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BLFS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BLFS
Boston Scientific (BSX) Q1 Earnings and Revenues Top Estimates
New Strong Sell Stocks for October 9th
BLFS: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for September 13th
BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Misses Revenue Estimates
Stryker (SYK) Q2 Earnings and Revenues Beat Estimates
Other News for BLFS
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Intra-Cellular Therapies (ITCI)
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Alimera (ALIM)
Meta Platforms, Pure Storage And 2 Other Stocks Insiders Are Selling
Insider Sell: Chief Marketing Officer Todd Berard Sells 10,000 Shares of BioLife Solutions Inc ...
BioLife Solutions Announces the Divestiture of its Stirling Freezer Business